MedTrace Logo

Maxi-Analgesic Osteoarthritis (OA) Study

NCT01420666 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-01-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo in patients who have painful osteoarthritis of the hip or knee.

Conditions

Interventions

DRUG

Acetaminophen

Acetaminophen 325 mg, three tablets four times a day, orally, with food

DRUG

Maxigesic 325

Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food

DRUG

Ibuprofen

Ibuprofen 97.5mg, three tablets four times a day, orally, with food

DRUG

Placebo

placebo, three tablets four times a day, orally, with food

Sponsors & Collaborators

  • AFT Pharmaceuticals, Ltd.

    lead INDUSTRY

Principal Investigators

  • John Moodie, Doctor · Clinical Trial New Zealand Ltd, 32 Kahikatea Drive, Hamilton, New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420666 on ClinicalTrials.gov